This deficiency of strong evidence of affected individual Rewards is exemplified in the case of experienced infectious disorder products (QIDP). The FDA can approve a different antibiotic without having added clinical advantage for an “unmet clinical want” without proof demonstrating included Rewards for anyone people, as being the antibiotic https://proleviate.com/